A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025- Completed ...

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with ...

LIXTE Biotechnology (LIXT) has added the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as a second site in a clinical ...

Lurie Cancer Center initiates trial combining LIXTE's LB-100 and GSK's Dostarlimab for ovarian clear cell cancer treatment. LIXTE Biotechnology Holdings, Inc. has announced that the Robert H.

Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology ...

J&J has reached several deals with pharma companies permitting biosimilar commercialisation after Stelara’s patent expired in July 2024. Image credit: Shutterstock/ Michael Vi. Johnson & Johnson (J&J) ...